114 related articles for article (PubMed ID: 37315698)
21. Isoxazolo(aza)naphthoquinones: a new class of cytotoxic Hsp90 inhibitors.
Bargiotti A; Musso L; Dallavalle S; Merlini L; Gallo G; Ciacci A; Giannini G; Cabri W; Penco S; Vesci L; Castorina M; Milazzo FM; Cervoni ML; Barbarino M; Pisano C; Giommarelli C; Zuco V; De Cesare M; Zunino F
Eur J Med Chem; 2012 Jul; 53():64-75. PubMed ID: 22538015
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
Schwock J; Pham NA; Cao MP; Hedley DW
Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
[TBL] [Abstract][Full Text] [Related]
23. Non-benzoquinone geldanamycin analogs trigger various forms of death in human breast cancer cells.
Zhang Z; Li HM; Zhou C; Li Q; Ma L; Zhang Z; Sun Y; Wang L; Zhang X; Zhu B; Hong YS; Wu CZ; Liu H
J Exp Clin Cancer Res; 2016 Sep; 35(1):149. PubMed ID: 27658586
[TBL] [Abstract][Full Text] [Related]
24. Design, synthesis and pharmacological evaluation of 4,5-diarylisoxazols bearing amino acid residues within the 3-amido motif as potent heat shock protein 90 (Hsp90) inhibitors.
Zhang C; Wang X; Liu H; Zhang M; Geng M; Sun L; Shen A; Zhang A
Eur J Med Chem; 2017 Jan; 125():315-326. PubMed ID: 27688186
[TBL] [Abstract][Full Text] [Related]
25. Prediction of new Hsp90 inhibitors based on 3,4-isoxazolediamide scaffold using QSAR study, molecular docking and molecular dynamic simulation.
Abbasi M; Sadeghi-Aliabadi H; Amanlou M
Daru; 2017 Jun; 25(1):17. PubMed ID: 28666484
[TBL] [Abstract][Full Text] [Related]
26. Heat Shock Protein 90 Inhibitor Effects on Pancreatic Cancer Cell Cultures.
Gulla A; Kazlauskas E; Liang H; Strupas K; Petrauskas V; Matulis D; Eshleman JR
Pancreas; 2021 Apr; 50(4):625-632. PubMed ID: 33939678
[TBL] [Abstract][Full Text] [Related]
27. Discovery of 5-aryl-3-thiophen-2-yl-1H-pyrazoles as a new class of Hsp90 inhibitors in hepatocellular carcinoma.
Mohamady S; Ismail MI; Mogheith SM; Attia YM; Taylor SD
Bioorg Chem; 2020 Jan; 94():103433. PubMed ID: 31785857
[TBL] [Abstract][Full Text] [Related]
28. A Novel Class of Hsp90 C-Terminal Modulators Have Pre-Clinical Efficacy in Prostate Tumor Cells Without Induction of a Heat Shock Response.
Armstrong HK; Koay YC; Irani S; Das R; Nassar ZD; ; Selth LA; Centenera MM; McAlpine SR; Butler LM
Prostate; 2016 Dec; 76(16):1546-1559. PubMed ID: 27526951
[TBL] [Abstract][Full Text] [Related]
29. Strong anti-tumor effect of NVP-AUY922, a novel Hsp90 inhibitor, on non-small cell lung cancer.
Ueno T; Tsukuda K; Toyooka S; Ando M; Takaoka M; Soh J; Asano H; Maki Y; Muraoka T; Tanaka N; Shien K; Furukawa M; Yamatsuji T; Kiura K; Naomoto Y; Miyoshi S
Lung Cancer; 2012 Apr; 76(1):26-31. PubMed ID: 21996088
[TBL] [Abstract][Full Text] [Related]
30. Novel HSP90 inhibitors, NVP-AUY922 and NVP-BEP800, radiosensitise tumour cells through cell-cycle impairment, increased DNA damage and repair protraction.
Stingl L; Stühmer T; Chatterjee M; Jensen MR; Flentje M; Djuzenova CS
Br J Cancer; 2010 May; 102(11):1578-91. PubMed ID: 20502461
[TBL] [Abstract][Full Text] [Related]
31. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.
Donnelly A; Blagg BS
Curr Med Chem; 2008; 15(26):2702-17. PubMed ID: 18991631
[TBL] [Abstract][Full Text] [Related]
32. Discovery of novel anti-breast cancer agents derived from deguelin as inhibitors of heat shock protein 90 (HSP90).
Nguyen CT; Ann J; Sahu R; Byun WS; Lee S; Nam G; Park HJ; Park S; Kim YJ; Kim JY; Seo JH; Lee J
Bioorg Med Chem Lett; 2020 Sep; 30(17):127374. PubMed ID: 32738983
[TBL] [Abstract][Full Text] [Related]
33. Gephyromycin C, a novel small-molecule inhibitor of heat shock protein Hsp90, induces G2/M cell cycle arrest and apoptosis in PC3 cells in vitro.
Ding WJ; Ji YY; Jiang YJ; Ying WJ; Fang ZY; Gao TT
Biochem Biophys Res Commun; 2020 Oct; 531(3):377-382. PubMed ID: 32800334
[TBL] [Abstract][Full Text] [Related]
34. Novel 3,4-isoxazolediamides as potent inhibitors of chaperone heat shock protein 90.
Baruchello R; Simoni D; Grisolia G; Barbato G; Marchetti P; Rondanin R; Mangiola S; Giannini G; Brunetti T; Alloatti D; Gallo G; Ciacci A; Vesci L; Castorina M; Milazzo FM; Cervoni ML; Guglielmi MB; Barbarino M; Foderà R; Pisano C; Cabri W
J Med Chem; 2011 Dec; 54(24):8592-604. PubMed ID: 22066525
[TBL] [Abstract][Full Text] [Related]
35. NMS-E973, a novel synthetic inhibitor of Hsp90 with activity against multiple models of drug resistance to targeted agents, including intracranial metastases.
Fogliatto G; Gianellini L; Brasca MG; Casale E; Ballinari D; Ciomei M; Degrassi A; De Ponti A; Germani M; Guanci M; Paolucci M; Polucci P; Russo M; Sola F; Valsasina B; Visco C; Zuccotto F; Donati D; Felder E; Pesenti E; Galvani A; Mantegani S; Isacchi A
Clin Cancer Res; 2013 Jul; 19(13):3520-32. PubMed ID: 23674492
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis, and molecular docking studies of novel pyrazolyl 2-aminopyrimidine derivatives as HSP90 inhibitors.
Mettu A; Talla V; Bajaj DM; Subhashini NJP
Arch Pharm (Weinheim); 2019 Oct; 352(10):e1900063. PubMed ID: 31411362
[TBL] [Abstract][Full Text] [Related]
37. New heat shock protein (Hsp90) inhibitors, designed by pharmacophore modeling and virtual screening: synthesis, biological evaluation and molecular dynamics studies.
Abbasi M; Amanlou M; Aghaei M; Bakherad M; Doosti R; Sadeghi-Aliabadi H
J Biomol Struct Dyn; 2020 Aug; 38(12):3462-3473. PubMed ID: 31452440
[TBL] [Abstract][Full Text] [Related]
38. Preclinical antitumor activity of SST0116CL1: a novel heat shock protein 90 inhibitor.
Vesci L; Milazzo FM; Carollo V; Pace S; Giannini G
Int J Oncol; 2014 Oct; 45(4):1421-9. PubMed ID: 25096516
[TBL] [Abstract][Full Text] [Related]
39. Comparative effects of SNX-7081 and SNX-2112 on cell cycle, apoptosis and Hsp90 client proteins in human cancer cells.
Wang X; Wang S; Liu Y; Huang D; Zheng K; Zhang Y; Wang X; Liu Q; Yang D; Wang Y
Oncol Rep; 2015 Jan; 33(1):230-8. PubMed ID: 25334086
[TBL] [Abstract][Full Text] [Related]
40. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells.
Zhang T; Hamza A; Cao X; Wang B; Yu S; Zhan CG; Sun D
Mol Cancer Ther; 2008 Jan; 7(1):162-70. PubMed ID: 18202019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
